Nanobiotix reports early lung cancer trial data for JNJ-1900 treatment

May 17, 2026 10:15 AM

Nanobiotix (Euronext: NANO, NASDAQ: NBTX) announced results from Part 1 of the CONVERGE study, a Johnson & Johnson-sponsored randomized Phase ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found